Genitourinary Cancers Symposium (ASCO GU) | Conference

Dr. Aggarwal on Characteristics Associated With PSA PFS from the PRESTO Trial in Prostate Cancer

February 17th 2023

Rahul Aggarwal, MD, discusses the association between baseline characteristics and prostate-specific antigen progression-free survival in patients with high-risk biochemically relapsed prostate cancer from the phase 3 PRESTO trial.

Dr. Agarwal on the Efficacy of Talazoparib Plus Enzalutamide in First-line mCRPC

February 17th 2023

Neeraj Agarwal, MD, discusses the efficacy of talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.

Ra-223 Displays Efficacy, Safety in mCRPC With Bone Metastases

February 17th 2023

Radium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.

Sacituzumab Govitecan Benefit Is Consistent Following CPI in Platinum-Ineligible mUC

February 17th 2023

Treatment with the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan elicited an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer following progression on an immune checkpoint inhibitor, according to the primary analysis of TROPHY-U-01 cohort 2.

Potential Biomarkers of Response Identified for Enfortumab Vedotin in Advanced Urothelial Cancer

February 17th 2023

Tumor mutational burden and alterations in CDKN2A, CDKN2B, and MTAP were among several biomarkers that were predictive of response to enfortumab vedotin in patients with advanced urothelial carcinoma, according to findings from a retrospective analysis.

TURBT Plus Chemoimmunotherapy Triplet Induces Complete Responses in MIBC

February 17th 2023

Transurethral resection of bladder tumor followed by gemcitabine, cisplatin, and nivolumab led to stringent clinical complete responses in patients with muscle-invasive bladder cancer.

Dr. Galsky on Updated Findings From the CheckMate-274 Trial in Urothelial Cancer

February 17th 2023

Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.

Dr. Necchi on Key Results From Cohort B of the KEYNOTE-057 Trial in MIBC

February 17th 2023

Andrea Necchi, MD, discusses updated analysis of cohort B in the phase 2 KEYNOTE-057 trial in non-muscle invasive bladder cancer.

Darolutamide Demonstrates Long-term Safety in nmCRPC

February 16th 2023

Darolutamide maintained an acceptable long-term safety profile in patients with nonmetastatic castration-resistant prostate cancer, with approximately 30% of patients remaining on the treatment for at least 4 years

Lutetium 177 PSMA-617 Following Radium-223 Is Active and Safe in mCRPC

February 16th 2023

Sequencing treatment with Lutetium 177 PSMA-617 after radium-223 was safe and well tolerated and demonstrated similar overall survival in patients with metastatic castration-resistant prostate cancer regardless of whether they received 177Lu-PSMA-617 within 6 months or after 6 months of completing radium-223.

Dr. Hadaschik on Treatment After Apalutamide Progression in SPARTAN Trial

February 16th 2023

Boris A. Hadaschik, MD, discusses a post-hoc analysis of subsequent therapies received by patients with prostate cancer treated with apalutamide during the phase 3 SPARTAN trial.

Dr. Tombal on the OS Benefit of Darolutamide Plus ADT/Docetaxel in mHSPC

February 16th 2023

Bertrand Tombal, MD, PhD, discusses the overall survival benefit associated with androgen-deprivation therapy plus darolutamide in metastatic hormone-sensitive prostate cancer.

Darolutamide Plus ADT/Docetaxel Elicits Survival Benefit Across Subgroups in mHSPC

February 16th 2023

The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.

Darolutamide Demonstrates Favorable Tolerability, Decreased Metastatic Progression in nmCRPC

February 16th 2023

Treatment with darolutamide decreased the likelihood of developing metastatic disease or discontinuing treatment because of adverse effects vs treatment with apalutamide or enzalutamide in patients with non-metastatic castration-resistant prostate cancer.

Adjuvant Mitotane Fails to Improve RFS in Patients with ACC at Low/Intermediate Risk of Recurrence

February 20th 2022

The utilization of mitotane in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma at low or intermediate risk of recurrence.

Adjuvant Pembrolizumab Maintains DFS Benefit in High-Risk RCC

February 20th 2022

Adjuvant pembrolizumab continued to demonstrate improved disease-free survival placebo in patients with renal cell carcinoma who are at high risk of recurrence.

Dr. Choueiri on the Follow-Up Analysis of KEYNOTE-564 in RCC

February 19th 2022

Toni Choueiri, MD, discusses the 30-month follow-up analysis of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Superior Health-Related QOL Outcomes With Nivolumab/Cabozantinib Endure in RCC

February 19th 2022

At a nearly 3-year median follow-up, health-related quality-of-life scores were improved or maintained over time among patients with advanced renal cell carcinoma who received with nivolumab plus cabozantinib compared with those who received sunitinib.

Lenvatinib Plus Pembrolizumab Produces Consistent Efficacy in East Asian Subset With Advanced RCC

February 19th 2022

The combination of lenvatinib and pembrolizumab produced similar efficacy and safety profiles in an East Asian subgroup of patients with advanced renal cell carcinoma.

Immune Cell–Related Parameters May Serve as Biomarkers for Response to Nivolumab/Ipilimumab in Clear Cell RCC

February 19th 2022

Efficacy rates generated by the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) vary based on certain immune-cell related parameters in patients with advanced or metastatic clear cell renal cell carcinoma.